中文：

国药股份是一家大型医药企业，其股票在市场上具有较高的知名度和关注度。然而，自2023年4月14日起，该公司因重大事项宣布停牌，引起了广泛关注。那么，国药股份什么时候复牌呢？

据相关公告，国药股份已于2023年5月9日召开董事会审议通过了《关于终止重大资产重组事项的议案》，这意味着该公司将不再进行此前宣布的重大资产重组。此外，国药股份还表示，公司股票将于2023年5月10日开市起复牌。

对于国药股份的复牌，市场反应不一。一些投资者认为，该公司终止重大资产重组可能会对公司的未来发展产生一定的影响，因此他们对复牌后的股价走势持谨慎态度。而另一些投资者则认为，国药股份在经过一段时间的停牌后，已经对市场做出了充分的调整和准备，因此他们对复牌后的股价走势持乐观态度。

总的来说，国药股份的复牌对于市场和投资者来说都是一个重要的信号。这不仅意味着该公司已经结束了重大资产重组的计划，还意味着该公司已经准备好迎接未来的挑战和机遇。因此，投资者应该密切关注国药股份的动态，以便做出明智的投资决策。

英文：

Guoyao Pharmaceutical, a large pharmaceutical company, has a high profile and attention in the market. However, since April 14, 2023, the company announced a suspension of its shares due to major matters, which attracted widespread attention. So, when will Guoyao Pharmaceutical resume trading?

According to relevant announcements, Guoyao Pharmaceutical held a board meeting on May 9, 2023 to consider the termination of the significant asset restructuring plan. This means that the company will no longer proceed with the significant asset restructuring announced earlier. In addition, Guoyao Pharmaceutical also stated that the company's shares will resume trading on May 10th, 2023.

The market reaction to Guoyao Pharmaceutical's resumption of trading is mixed. Some investors believe that the termination of the significant asset restructuring plan may have an impact on the company's future development, so they are cautious about the stock price trend after resumption. Others believe that Guoyao Pharmaceutical has made sufficient adjustments and preparations after the suspension of trading, so they are optimistic about the stock price trend after resumption.

Overall, Guoyao Pharmaceutical's resumption of trading is an important signal for the market and investors. This not only means that the company has ended its significant asset restructuring plan but also means that the company is ready to face future challenges and opportunities. Therefore, investors should pay close attention to Guoyao Pharmaceutical's dynamic in order to make wise investment decisions.